

Rule 4.3A

## Appendix 4E

### Preliminary final report for the financial year ended 30 June 2021

Name of entity

**VECTUS BIOSYSTEMS LIMITED** ABN: 54 117 526 137**Reporting period:** 30 June 2021**Previous period:** 30 June 2020**Results for announcement to the market**

				\$A'000
Revenues from ordinary activities	up	59%	to	81,590
Loss from ordinary activities after tax attributable to	up	43%	to	(4,282,569)
Loss for the period attributable to owners of Vectus Biosystems Limited	up	43%	to	(4,282,569)

Dividends (distributions)	Amount per security	Franked amount per security
	Final dividend	Nil ¢
Previous corresponding period	Nil ¢	Nil ¢

**Brief explanation of the above**

The Group has incurred an operating loss of \$4,282,569 for the year ended 30 June 2021 (2020: \$2,996,071) and net equity deficit has moved from \$5,644,613 as at 30 June 2020 to \$2,822,602 as at 30 June 2021. The operating cash burn rate for the year ended 30 June 2021 was \$3,255,532 (2020: \$3,001,547). The cash balance as at 30 June 2021 was \$5,778,124.

This Appendix 4E should be read in conjunction with the Half Year Financial Report of the Group as at 31 December 2020. It is also recommended that the Appendix 4E be considered together with any public announcements made by the Group since commencement of the 2020-21 financial year in accordance with the continuous disclosure obligations arising under the *Corporations Act 2001*.

**NTA backing**

Net tangible asset backing per ordinary share

**30-Jun-21**  
**cents**  
(8.92)

**30-Jun-20**  
**cents**  
(23.86)

**Events occurring after Balance Date**

No matter or circumstance has arisen since 30 June 2021 that has significantly affected or may significantly affect the consolidated entities' operations, the results of these operations, or the consolidated entities' state of affairs in future financial years.

**Details of entities over which control has been gained or lost during the period**

Not Applicable

**Foreign Entities details**

Not Applicable

**Dividends**

No dividends were paid or proposed during the financial year.

**Audit or Review details**

This report is based on audited accounts.

**Annual Financial Report**

The Vectus Biosystems Limited audited Annual Financial Report for the year ended 30 June 2021 accompanies this announcement. Additional Appendix 4E disclosure requirements can be found in the Directors' Report, the Review of Operations and the 30 June 2021 financial statements and accompanying notes in the Annual Financial Report.



Sign here:

(Director/Company Secretary)

Print name: **Robert J Waring**Date: **31 August 2021**